Lilly Bio-Medicines comprise the largest of Lilly’s five business areas in terms of sales, and account for nearly half of Lilly’s mid-to-late stage pipeline assets. This business unit is unique in that it focuses on multiple therapeutic areas.
Lilly Diabetes remains committed to meeting the needs of people with diabetes from medicines to support programs, including investments in one of our largest diabetes' pipelines ever.
A global division of Lilly, Elanco works to develop and market products that improve animal health and protein production in more than 75 countries across the globe.
We work to deliver innovative medicines that address unmet needs around the world. More than 6,000 employees in 30 Lilly affiliates work across the 70 countries that make up Lilly's Emerging Markets business.
As one of the top 10 oncology companies in the world, Lilly Oncology focuses on speeding innovation and improving outcomes for individual patients, and boasts one of the largest clinical pipelines in the oncology industry.